Sub-Licensing AvailableDear Sir, Munogenics, Inc. develops, tests, and licenses novel biological methods for treating and preventing malignant diseases in humans. The company has a proprietary revolutionary platform for cancer treatment that shows exceptional efficacy and minimal side effect in treating cancers. In collaboration with a research team led by Dr. Zheng Cui, MD / PhD and Dr. Mark C. Willingham, MD, at Wake Forest University, Munogenics will commercialize a new cancer treatment, termed the GIFT (Granulocyte InFusion Therapy) process, and the CKA (Cancer Killing Activity) test with the Jtechnow is a currently seeking to sub-license GIFT and CKA testing in select countries around the world. Our research clearly demonstrates that granulocyte infusion, at optimal levels, translates to an unprecedented regression of cancer. To obtain more information about bringing GIFT to a country, please contact us. We will be happy to provide all of the information you need. we await your replyLathell Sancho